Transcatheter Aortic Valve Replacement
66
13
14
23
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.5%
3 terminated out of 66 trials
88.5%
+1.9% vs benchmark
18%
12 trials in Phase 3/4
17%
4 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 23 completed trials
Clinical Trials (66)
CT TAVR Abdomen Study
This Study Will Evaluate the Safety and Potential Complications of Dual ProGlide vs Single ProGlide and Angioseal for Common Femoral Arteriotomy Closure Following Transcatheter Aortic Valve Replacement
Comparison of Single vs. Dual Perclose Devices for Large-Bore Access Closure in TAVR
Transcatheter Mitral and Tricuspid Interventions: a Cardiac Magnetic Resonance Study
Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR
Coronary Artery Disease Assessment Strategies in TAVI Patients
COronary Re-engageMent aFter randOm NavitoR alignmenT (COMFORT STUDY)
Ischemic And Bleeding Risk Assessment After TAVR
Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.
Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement
TAVR for Aortic Regurgitation Under TEE Guidance
Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients
Efficacy and Safety of Ciprofol for General Anaesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement
Monitored Anesthesia Care vs. General Anesthesia for Transcatheter Aortic Valve Replacement
The Sentinel Registry
Intra-procedural ECG Changes During TAVR
Cara CDRM (Conduction Disturbance Risk Monitor) 2.0
Cara CDRS (Conduction Disturbance Risk Score) 1.0
Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)